Nexalin Technology, Inc.

NXL Nasdaq CIK: 0001527352

Company Information

Industry Electromedical & Electrotherapeutic Apparatus
SIC Code 3845
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 1776 YORKTOWN, HOUSTON, TX, 77056
Mailing Address 1776 YORKTOWN, HOUSTON, TX, 77056
Phone (832) 260-0222
Fiscal Year End 1231
EIN 275566468

Financial Overview

FY2025 FY

$302K
Revenue
-$7.61M
Net Income

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 25, 2026 View on SEC
8-K Current report of material events February 25, 2026 View on SEC
8-K Current report of material events January 23, 2026 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
4 Insider stock transaction report December 23, 2025 View on SEC
8-K Current report of material events December 5, 2025 View on SEC

Annual Reports

10-K March 25, 2026
  • Innovative 'razor-and-blade' business model using proprietary smart electrodes for recurring revenue.
  • Development of advanced Gen-2 and Gen-3 neurostimulation devices for mental health.
View Analysis

Material Events

8-K Financial Distress January 23, 2026
High Impact
  • The Nasdaq deficiency notice does not immediately affect the listing or trading of the Company’s common stock.
  • The Company has an initial 180-calendar-day period, until July 20, 2026, to regain compliance.
View Analysis

Related Companies

Companies in the same industry (SIC: 3845)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.